About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study of REGN3500 and Dupilumab in Patients With Asthma

NCT03112577·5 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Regeneron Pharmaceuticals

With

Sanofi

Age

18–60

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Male or female aged between 18 and 60 years
2. Has a Body Mass Index {BMI) of 17 to 33 kg/m2 at pre-study screening
3. Has a history of mild allergic asthma for at least 6 months
4. Is a non-smoker or ex-smoker for at least 12 months

You may not be if

1. Has a history of life-threatening asthma
2. Has been hospitalized or has attended the emergency room for asthma in the 12 months prior to screening
3. Has a history of severe allergies or history of an anaphylactic reaction
4. Has a history of drug or alcohol abuse within a year prior to the screening visit

The record

StatusCompleted

PhasePhase 1

Taking part32

StartedJun 2017

UpdatedJan 18, 2020

Conditions

Asthma, Allergic

Where5

WCCT Global
Cypress, California, United States
Celerion
Belfast, United Kingdom
Hammersmith Medicine Research
London, United Kingdom

Clareo Health | Study of REGN3500 and Dupilumab in Patients With Asthma